Hemispherx BioPharma, Inc (NYSEMKT:HEB)
The market sent shares of Hemispherx BioPharma, Inc (NYSEMKT:HEB) higher after the company issued a status update that the market perceived as positive to its long-term prospects. The shares rose about 1.0% to $0.52.
But the stock has had a rough run this year. It is down about 24.6% since the beginning of the year and down about 62.3% over the last 12 months.
The update that moved HEB Shares
Hemispherx BioPharma, Inc (NYSEMKT:HEB) issued a press release that 12 patients afflicted by pancreatic cancer were being treated by its experimental drug Ampligen, which is an immuno-oncology therapy. Those patients are receiving the treatment in the Netherlands and the experimental treatment program, titled the Early Access Program (EAP), is managed by myTomorrows – an Amsterdam-based organization that provides physician access to experimental medicines.
Hemispherx said that eight of the twelve patients receiving Ampligen under EAP enrolled with late-stage condition of pancreatic cancer, while the other four enrolled with early-stage condition of the disease.
Can Ampligen reduce disease progression and increase patient survival?
The aim of the EAP program is to assess the impact of Ampligen on people afflicted by pancreatic cancer. As such, the focus is on the ability of Ampligen to reduce disease progression and increase survival of patients who have run out of conventional treatment options of pancreatic cancer.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) said that a leading Dutch oncologist and specialist in pancreatic cancer was overseeing the experimental treatment with Ampligen under the EPA program.
Hemispherx BioPharma, Inc (NYSEMKT:HEB)’s CEO Thomas K. Equels noted that Ampligen is well-tolerated by patients already receiving the treatment under the EAP program.
Equels also recalled that prior studies had shown that Ampligen possesses tumor-killing and immuno-modulating characteristics, adding that these capabilities form the basis of immuno-oncology therapy.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) is receiving compensation from the government of Netherlands for the experimental use of Ampligen in the EAP program. Up to 50 pancreatic cancer patients will receive Ampligen treatment under the program.
In addition to Netherlands, is Hemispherx wants to make Ampligen available in other European countries with government reimbursements. The company is also eyeing the US for the drug trial.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) develops therapies designed to treat debilitating diseases such as cancer. The company’s flagship products include Alferon and Ampligen (rintatolimod). These products haven’t received FDA approval and are only available for use in clinical trials.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $HEB and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.